Table 1 Demographic and clinical data of the study population

Participants, n (%)

9 (18.0)

7 (14.0)

23 (46.0)

11 (22.0)^a

50 (100.0)

Female, n (%)

7 (14.0)

3 (6.0)

18 (36.0)

10 (20.0)

38 (76.8)

Age; median years (max-min)

30 (18 to 37)

31 (20 to 47)

37 (19 to 66)

29 (25 to 46)

32 (18 to 66)

Ethnicity, n (%)

White

8 (16.0)

5 (10.0)

13 (26.0)

9 (18.0)

35 (70.0)

African American

0 (0.0)

1 (2.0)

4 (8.0)

1 (2.0)

6 (12.0)

Hispanic

0 (0.0)

0 (0.0)

3 (6.0)

0 (0.0)

3 (6.0)

Other

1 (2.0)

1 (2.0)

3 (6.0)

1 (2.0)

6 (12.0)

Atopic, n (%)

1 (2.0)

7 (14.0)

18 (36.0)

8 (16.0)

34 (68.0)

Baseline PC ₂₀ ; mean mg/mL (±SD)

28 (27.1)

6.7 (3.8)

4.5 (5.1)

4.4 (5.2)

n/a

Baseline FEV1; mean% predicted (±SD)

98.3 (11.0)

105.8 (6.7)

97.8 (16.5)

91.2 (10.8)

n/a

Medication, n (%)

Inhaled corticosteroids

0 (0.0)

0 (0.0)

6 (12.0)

3 (6.0)

9 (18.0)

Inhaled corticosteroids plus long-acting beta agonists

0 (0.0)

0 (0.0)

2 (4.0)

1 (2.0)

3 (6.0)

Nasal steroids

0 (0.0)

0 (0.0)

6 (12.0)

3 (6.0)

9 (18.0)

Respiratory virus identification, n (%)

Human rhinovirus

5 (10.0)

1 (2.0)

9 (18.0)

3 (6.0)

18 (36.0)

Respiratory syncytial virus

0 (0.0)

0 (0.0)

2 (4.0)

1 (2.0)^b

3 (6.0)

Human coronavirus

1 (2.0)

1 (2.0)

2 (4.0)

2 (4.0)^b

6 (12.0)

Influenza A virus

0 (0.0)

1 (2.0)

1 (2.0)

0 (0.0)

2 (4.0)

Human parainfluenza virus

0 (0.0)

1 (2.0)

0 (0.0)

0 (0.0)

1 (2.0)

No detection

3 (6.0)

3 (6.0)

9 (18.0)

5 (10.0)

20 (40.0)